Skip to main content
SPRB logo

Spruce Biosciences, Inc.

SPRBNASDAQHealthcareBiotechnology

$41.47Today:- (-)1Y −73.52%

As of Oct 15, 2026 close

Market cap
$100.82M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$38.06$179.95
Volume (live)
-
Avg. volume (3M)
95.64K

Spruce Biosciences (SPRB) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Spruce Biosciences used $33.33M of cash in operating activities. Free cash flow was −$33.33M. It repurchased $831.00K of its own shares.

Spruce Biosciences Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Spruce Biosciences, Inc. (SPRB) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-38.97-53.04-47.92-46.18-42.29-29.54-13.09-9.86
Depreciation & Amortization0.020.050.070.070.070.040.010.00
Stock Based Compensation2.575.354.623.633.960.760.200.10
Change in Working Capital-0.72-8.5710.361.131.961.160.261.19
Change in Accounts Payable-0.35-2.041.91-1.40-0.813.73-0.231.70
Change in Other Working Capital0.270.658.45-1.062.76-2.570.49-0.51
Other Operating Activities0.270.25-0.40-0.340.430.070.00-1.59
Net Cash from Operating Activities-33.33-55.96-33.28-41.68-35.88-27.52-12.62-8.57
Investing Activities
Capital Expenditures0.000.00-0.01-0.01-0.09-0.070.000.00
Purchases of Investments0.000.00-11.8823.70-79.080.000.000.00
Sales/Maturities of Investments0.000.0067.6760.500.000.000.000.00
Net Cash from Investing Activities0.000.0055.7823.69-79.17-0.070.000.00
Financing Activities
Debt Repayment-2.06-1.62-1.620.000.220.004.490.00
Common Stock Issued50.000.2553.620.080.4693.350.000.00
Common Stock Repurchased-0.83-0.250.00-0.040.000.000.000.00
Other Financing Activities-4.53-0.25-2.85-0.28-0.0487.687.940.00
Net Cash from Financing Activities43.48-1.6249.14-0.240.64181.0412.430.00
Summary
Effect of Forex Changes on Cash0.000.000.000.190.000.000.000.00
Net Change in Cash10.15-57.5971.64-18.23-114.40153.44-0.19-8.57
Cash at Beginning of Period38.7996.3724.7342.96157.373.924.1112.68
Cash at End of Period48.9438.7996.3724.7342.96157.373.924.11
Free Cash Flow-33.33-55.96-33.28-41.69-35.97-27.59-12.62-8.57
Supplemental Disclosures
Interest Paid0.070.230.370.270.210.19--

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Spruce Biosciences Cash Flow

What is Spruce Biosciences's free cash flow?

Spruce Biosciences had negative free cash flow of $33.33M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does Spruce Biosciences pay dividends or buy back shares?

Yes. In fiscal 2025 Spruce Biosciences returned $831.00K in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition